Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Theranostics|July 1, 2024
Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinomaSimone C Kleinendorst, Egbert Oosterwijk, Janneke Molkenboer-Kuenen, et al.
European Urology|August 12, 2008
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinomaBernd Wagner, Jean-Jacques Patard, Arnaud Méjean, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2012
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancerJohn Dulos, Gregory J Carven, Susan J van Boxtel, et al.
BJU International|October 27, 2021
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trialYasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 20, 2025
The impact of the new WHO Classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinomaJan Degenhardt, Yuri Tolkach, Mahul B Amin, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
BMJ Open|August 29, 2023
TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessmentTessa van Elst, Jean-Paul van Basten, Pieter van den Berg, et al.
Psychological Medicine|July 24, 2023
Development and validation of a multimodal neuroimaging biomarker for electroconvulsive therapy outcome in depression: a multicenter machine learning analysisWillem Benjamin Bruin, Leif Oltedal, Hauke Bartsch, et al.
JAMA Oncology|December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical TrialAxel Bex, Peter Mulders, Michael Jewett, et al.
Pageof 7